Novartis Eyes Fourth Approval For Cosentyx
An nr-axSpA okay will boost Swiss major's biggest seller
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.
